Global Trends in Research of Amino Acid Metabolism in T Lymphocytes in Recent 15 Years: A Bibliometric Analysis

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2025 Feb 14

PMID 39950085

Authors

Jiaona Xu

Yinan Yu

Shijie Li

Fanghui Qiu

Affiliations

Soon will be listed here.

Abstract

Amino acid metabolism in T cells determines the therapeutic efficacy of T-cell-targeting drugs. To assess the direction of amino acid metabolism in T cells and construct related knowledge structure, we performed a bibliometric analysis aiming at amino acid metabolism in T cells utilizing studies publicized in recent 15 years. Three hundred thirty-seven related studies were downloaded from the Web of Science Core Collection (WoSCC), and the information on countries, institutes, and authors was collected and analyzed. In addition, the present research status and future trends were explored according to the results yielded from the analysis of cited references and keywords. This study revealed that publications regarding amino acid metabolism in T cells gradually increased each year. The USA is the top producer and most influential country in this field. Recent research has focused on the correlation between the metabolism of several amino acids and regulatory T cells (Tregs) and CD8 T cells. Overall, this research offers a comprehensive exhibition on the field of amino acid metabolism in T cells, which will help researchers to study this domain more effectively and intuitively.

References

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

Choi B, Martinez-Falero I, Corset C, Munder M, Modolell M, Muller I . Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages. J Leukoc Biol. 2008; 85(2):268-77. PMC: 2642643. DOI: 10.1189/jlb.0508310. View

Sharma M, Baban B, Chandler P, Hou D, Singh N, Yagita H . Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007; 117(9):2570-82. PMC: 1940240. DOI: 10.1172/JCI31911. View

Phan A, Goldrath A, Glass C . Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity. Immunity. 2017; 46(5):714-729. PMC: 5505665. DOI: 10.1016/j.immuni.2017.04.016. View

Dong D, Sun M, Xu D, Han S, Cui L, Cao S . Mapping the Hot Spots and Evolution Main Path of Whole-Body Vibration Training Since the 21st Century: A Bibliometric Analysis. Front Bioeng Biotechnol. 2022; 10:920846. PMC: 9309814. DOI: 10.3389/fbioe.2022.920846. View

Jung K, LoRusso P, Burris H, Gordon M, Bang Y, Hellmann M . Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019; 25(11):3220-3228. PMC: 7980952. DOI: 10.1158/1078-0432.CCR-18-2740. View

Rodriguez P, Quiceno D, Ochoa A . L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2006; 109(4):1568-73. PMC: 1794048. DOI: 10.1182/blood-2006-06-031856. View

Labanieh L, Majzner R, Mackall C . Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2019; 2(6):377-391. DOI: 10.1038/s41551-018-0235-9. View

Lowe M, Boothby I, Clancy S, Ahn R, Liao W, Nguyen D . Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight. 2019; 4(24). PMC: 6975275. DOI: 10.1172/jci.insight.129756. View

10.

Palaskas N, Garcia J, Shirazi R, Shin D, Puig-Saus C, Braas D . Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discov. 2019; 5:62. PMC: 6877514. DOI: 10.1038/s41421-019-0130-x. View

11.

Li M, Guo W, Dong Y, Wang X, Dai D, Liu X . Elevated Exhaustion Levels of NK and CD8 T Cells as Indicators for Progression and Prognosis of COVID-19 Disease. Front Immunol. 2020; 11:580237. PMC: 7591707. DOI: 10.3389/fimmu.2020.580237. View

12.

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

13.

Abou-Alfa G, Qin S, Ryoo B, Lu S, Yen C, Feng Y . Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol. 2018; 29(6):1402-1408. DOI: 10.1093/annonc/mdy101. View

14.

Geiger R, Rieckmann J, Wolf T, Basso C, Feng Y, Fuhrer T . L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016; 167(3):829-842.e13. PMC: 5075284. DOI: 10.1016/j.cell.2016.09.031. View

15.

Matsuyama T, Yoshinaga S, Shibue K, Mak T . Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19. Cell Death Differ. 2021; 28(12):3199-3213. PMC: 8522258. DOI: 10.1038/s41418-021-00892-y. View

16.

OReilly E, Hechtman J . Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019; 30(Suppl_8):viii36-viii40. PMC: 6859823. DOI: 10.1093/annonc/mdz385. View

17.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

18.

Lemos H, Huang L, Prendergast G, Mellor A . Immune control by amino acid catabolism during tumorigenesis and therapy. Nat Rev Cancer. 2019; 19(3):162-175. DOI: 10.1038/s41568-019-0106-z. View

19.

Naik P, Zu J . Modeling and simulation of spatial-temporal calcium distribution in T lymphocyte cell by using a reaction-diffusion equation. J Bioinform Comput Biol. 2020; 18(2):2050013. DOI: 10.1142/S0219720020500134. View

20.

Ueda S, Hayashi H, Miyamoto T, Abe S, Hirai K, Matsukura K . Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes. Cancer Sci. 2018; 110(2):674-685. PMC: 6361610. DOI: 10.1111/cas.13908. View